drugset
drugset / Trial / NCT07460284

A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese Participants

NCT07460284 ↗

Phase 1 Not yet recruiting 8 enrolled Guangdong Raynovent Biotech Co., Ltd
NaSingle-groupOpen-labelBasic science

Summary

This is an open-label, single-center, single-dose study.

Timeline

Start
2026-03-15
Primary completion
2026-10-14
Completion
2026-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject RAY1225 Unknown — Subcutaneous

Indications

No indication recorded.